MAM
MPG appointed as media AOR for Vaswani Group
MUMBAI: MPG India, a flagship brand of Havas Media, has been appointed the media AOR of real estate company Vaswani Group.
The account, worth upwards of Rs 100 million, will be handled by MPG Bangalore. The agency won the account in a competitive pitch process.
MPG has been tasked with developing a media planning and buying strategy towards building an exclusive brand – The Vaswani Reserve.
Vaswani Group GM of marketing Joseph Angelo said: “We felt the MPG approach was thorough and insightful. Their strategic thinking, drive and passion instilled in us the confidence to believe that this will be a successful partnership.”
Commenting on the win, MPG South Asia CEO Anita Nayyar said: “It is a great privilege to be working with a very professional set of clients from Vaswani Group. The real estate space is booming in our country and the company has already created a niche for itself in commercial and residential property development arena. Partnering them in their journey is exciting and we are looking to play an important role in their next phase of growth. “
“One of the factors that helped us win this business was our strategic approach to communication mix using our proprietary tools. We made very targeted recommendations especially for consumer activation program.”
The Bangalore based Vaswani Group is a well-established property development company with strong presence and South India. The group has been in operation for the last 16 years and has developed eight million square feet of built area.
Brands
Bayer sues Johnson & Johnson over prostate cancer drug advertisements
Legal dispute begins as Bayer claims rival marketing is based on flawed data
NEW YORK: Bayer has filed a federal lawsuit against Johnson & Johnson (J&J) in New York, alleging that the American pharmaceutical company has used false and misleading advertisements to promote its prostate cancer treatment, Erleada. The dispute centres on claims that Erleada is significantly more effective than Bayer’s competing drug, Nubeqa.
The legal action follows a J&J marketing campaign that cited a 51 per cent reduction in the risk of death for patients using Erleada compared to those on Nubeqa. Bayer contends that these figures are based on a study with severe methodological errors rather than a controlled clinical trial.
Bayer’s legal team argues that J&J’s real-world analysis is fundamentally flawed. According to the complaint, J&J claimed to have 24 months of patient data supporting its conclusions, even though many patients included in the study had reportedly been on the medication for only a few months, raising concerns about the reliability of long-term survival comparisons.
The lawsuit also highlights what Bayer describes as a critical approval gap. For most of the period analysed in J&J’s study, Nubeqa had not yet been approved for the specific indication being evaluated, which Bayer argues makes a direct clinical comparison inappropriate and potentially misleading.
Additionally, Bayer contends that the study suffered from significant sample imbalance. The analysis reportedly included five times as many Erleada patients as Nubeqa patients, a disparity that Bayer says introduced statistical bias and undermined the validity of the findings.
Bayer is pursuing the case under the Lanham Act, the U.S. law governing false advertising and unfair competition. The company is seeking an immediate halt to J&J’s current marketing campaign and is asking the court to require corrective statements to physicians to address what it characterises as inaccurate claims.
Furthermore, Bayer is seeking monetary damages, arguing that the alleged misleading advertisements have resulted in lost revenue and reputational harm to Nubeqa.
Johnson & Johnson has responded by stating that it stands by the integrity of its data and the rigour of its analysis. The case will now proceed through the U.S. District Court for the Southern District of New York.
